{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:33:57Z","timestamp":1790818437816,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009032","name":"Pfizer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40273-024-01419-2","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T13:40:09Z","timestamp":1722606009000},"page":"1241-1253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Delay and Pay? Healthcare Costs Associated with Late Oral Anti-coagulant Prescribing in People with Atrial Fibrillation"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7250-7464","authenticated-orcid":false,"given":"Ryan J.","family":"Mulholland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Ciminata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry J.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin G.","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Lister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Geue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,2]]},"reference":[{"key":"1419_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j5058","volume":"359","author":"JA Lopez-Lopez","year":"2017","unstructured":"Lopez-Lopez JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017;359: j5058.","journal-title":"BMJ"},{"key":"1419_CR2","doi-asserted-by":"crossref","unstructured":"Lane DA, Skjoth F, Lip GYH, Larsen TB, Kotecha D. Temporal trends in incidence, prevalence, and mortality of atrial fibrillation in primary care. J Am Heart Assoc. 2017;6(5).","DOI":"10.1161\/JAHA.116.005155"},{"issue":"3","key":"1419_CR3","first-page":"195","volume":"14","author":"CA Morillo","year":"2017","unstructured":"Morillo CA, Banerjee A, Perel P, Wood D, Jouven X. Atrial fibrillation: the current epidemic. J Geriatr Cardiol. 2017;14(3):195\u2013203.","journal-title":"J Geriatr Cardiol"},{"issue":"3","key":"1419_CR4","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1161\/CIRCRESAHA.116.308407","volume":"120","author":"H Kamel","year":"2017","unstructured":"Kamel H, Healey JS. Cardioembolic stroke. Circ Res. 2017;120(3):514\u201326.","journal-title":"Circ Res"},{"issue":"11","key":"1419_CR5","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nrcardio.2014.118","volume":"11","author":"F Rahman","year":"2014","unstructured":"Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol. 2014;11(11):639\u201354.","journal-title":"Nat Rev Cardiol"},{"issue":"24","key":"1419_CR6","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1136\/heartjnl-2018-313350","volume":"104","author":"NJ Patel","year":"2018","unstructured":"Patel NJ, Atti V, Mitrani RD, Viles-Gonzalez JF, Goldberger JJ. Global rising trends of atrial fibrillation: a major public health concern. Heart. 2018;104(24):1989\u201390.","journal-title":"Heart"},{"issue":"2","key":"1419_CR7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jval.2011.09.009","volume":"15","author":"WP Wodchis","year":"2012","unstructured":"Wodchis WP, Bhatia RS, Leblanc K, Meshkat N, Morra D. A review of the cost of atrial fibrillation. Value Health. 2012;15(2):240\u20138.","journal-title":"Value Health."},{"issue":"23","key":"1419_CR8","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1161\/CIRCULATIONAHA.114.008201","volume":"129","author":"NJ Patel","year":"2014","unstructured":"Patel NJ, Deshmukh A, Pant S, Singh V, Patel N, Arora S, et al. Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning. Circulation. 2014;129(23):2371\u20139.","journal-title":"Circulation"},{"issue":"6","key":"1419_CR9","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1161\/CIRCULATIONAHA.118.035012","volume":"139","author":"JP Bassand","year":"2019","unstructured":"Bassand JP, Virdone S, Goldhaber SZ, Camm AJ, Fitzmaurice DA, Fox KAA, et al. Early risks of death, stroke\/systemic embolism, and major bleeding in patients with newly diagnosed atrial fibrillation. Circulation. 2019;139(6):787\u201398.","journal-title":"Circulation"},{"issue":"5","key":"1419_CR10","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.027211","volume":"12","author":"KK Lee","year":"2023","unstructured":"Lee KK, Doudesis D, Bing R, Astengo F, Perez JR, Anand A, et al. Sex differences in oral anticoagulation therapy in patients hospitalized with atrial fibrillation: a nationwide cohort study. J Am Heart Assoc. 2023;12(5): e027211.","journal-title":"J Am Heart Assoc"},{"key":"1419_CR11","doi-asserted-by":"publisher","first-page":"107602961987024","DOI":"10.1177\/1076029619870249","volume":"25","author":"CL Baker","year":"2019","unstructured":"Baker CL, Dhamane AD, Rajpura J, Mardekian J, Dina O, Russ C, et al. Switching to another oral anticoagulant and drug discontinuation among elderly patients with nonvalvular atrial fibrillation treated with different direct oral anticoagulants. Clin Appl Thromb Hemost. 2019;25:1076029619870249.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"2","key":"1419_CR12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10198-017-0873-y","volume":"19","author":"G de Lagasnerie","year":"2018","unstructured":"de Lagasnerie G, Aguade AS, Denis P, Fagot-Campagna A, Gastaldi-Menager C. The economic burden of diabetes to French national health insurance: a new cost-of-illness method based on a combined medicalized and incremental approach. Eur J Health Econ. 2018;19(2):189\u2013201.","journal-title":"Eur J Health Econ"},{"issue":"3","key":"1419_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-028575","volume":"10","author":"G Ciminata","year":"2020","unstructured":"Ciminata G, Geue C, Langhorne P, Wu O. A two-part model to estimate inpatient, outpatient, prescribing and care home costs associated with atrial fibrillation in Scotland. BMJ Open. 2020;10(3): e028575.","journal-title":"BMJ Open"},{"issue":"3","key":"1419_CR14","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1093\/ije\/dyw060","volume":"45","author":"S Alvarez-Madrazo","year":"2016","unstructured":"Alvarez-Madrazo S, McTaggart S, Nangle C, Nicholson E, Bennie M. Data resource profile: The Scottish National Prescribing Information System (PIS). Int J Epidemiol. 2016;45(3):714\u20135.","journal-title":"Int J Epidemiol"},{"issue":"1","key":"1419_CR15","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1136\/amiajnl-2011-000681","volume":"20","author":"NG Weiskopf","year":"2013","unstructured":"Weiskopf NG, Weng C. Methods and dimensions of electronic health record data quality assessment: enabling reuse for clinical research. J Am Med Inform Assoc. 2013;20(1):144\u201351.","journal-title":"J Am Med Inform Assoc"},{"key":"1419_CR16","unstructured":"ISD Scotland. Scottish health services costs book 2017\/18. https:\/\/www.isdscotland.org\/health-topics\/finance\/costs\/File-Listings-2018.asp."},{"key":"1419_CR17","unstructured":"ISD Scotland. Scottish health services costs book 2018\/19. https:\/\/www.isdscotland.org\/health-topics\/finance\/costs\/Detailed-Tables\/index.asp."},{"key":"1419_CR18","unstructured":"Public Health Scotland. Care home census-average weekly charges. https:\/\/www.opendata.nhs.scot\/dataset\/care-home-census\/resource\/4ee7dc84-ca65-455c-9e76-b614091f389f?view_id=80bbb82e-dcbc-4809-b837-2ca68358dfce."},{"issue":"10132","key":"1419_CR19","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/S0140-6736(18)30668-8","volume":"391","author":"T Gilbert","year":"2018","unstructured":"Gilbert T, Neuburger J, Kraindler J, Keeble E, Smith P, Ariti C, et al. Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study. Lancet. 2018;391(10132):1775\u201382.","journal-title":"Lancet"},{"key":"1419_CR20","unstructured":"Public Health Scotland. General practice\u2014disease prevalence data visualisation. https:\/\/publichealthscotland.scot\/publications\/general-practice-disease-prevalence-data-visualisation\/general-practice-disease-prevalence-visualisation-27-june-2023\/."},{"issue":"2","key":"1419_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/ehjqcco\/qcaa093","volume":"8","author":"P Burdett","year":"2022","unstructured":"Burdett P, Lip GYH. Atrial fibrillation in the UK: predicting costs of an emerging epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs. Eur Heart J Qual Care Clin Outcomes. 2022;8(2):187\u201394.","journal-title":"Eur Heart J Qual Care Clin Outcomes."},{"issue":"12","key":"1419_CR22","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1002\/pds.4333","volume":"26","author":"A Douros","year":"2017","unstructured":"Douros A, Renoux C, Coulombe J, Suissa S. Patterns of long-term use of non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation: Quebec observational study. Pharmacoepidemiol Drug Saf. 2017;26(12):1546\u201354.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"1419_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.21357","volume":"3","author":"N Chen","year":"2020","unstructured":"Chen N, Brooks MM, Hernandez I. Latent classes of adherence to oral anticoagulation therapy among patients with a new diagnosis of atrial fibrillation. JAMA Netw Open. 2020;3(2): e1921357.","journal-title":"JAMA Netw Open"},{"issue":"12","key":"1419_CR24","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011427","volume":"8","author":"I Hernandez","year":"2019","unstructured":"Hernandez I, He M, Chen N, Brooks MM, Saba S, Gellad WF. Trajectories of oral anticoagulation adherence among medicare beneficiaries newly diagnosed with atrial fibrillation. J Am Heart Assoc. 2019;8(12): e011427.","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"1419_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164076","volume":"11","author":"S Haas","year":"2016","unstructured":"Haas S, Ten Cate H, Accetta G, Angchaisuksiri P, Bassand JP, Camm AJ, et al. Quality of vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF Registry. PLoS ONE. 2016;11(10): e0164076.","journal-title":"PLoS ONE"},{"issue":"28","key":"1419_CR26","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1093\/eurheartj\/eht499","volume":"35","author":"L Azoulay","year":"2014","unstructured":"Azoulay L, Dell\u2019Aniello S, Simon TA, Renoux C, Suissa S. Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. Eur Heart J. 2014;35(28):1881\u20137.","journal-title":"Eur Heart J"},{"issue":"9","key":"1419_CR27","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.jacc.2006.10.062","volume":"49","author":"Y Miyasaka","year":"2007","unstructured":"Miyasaka Y, Barnes ME, Bailey KR, Cha SS, Gersh BJ, Seward JB, et al. Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J Am Coll Cardiol. 2007;49(9):986\u201392.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1419_CR28","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/ageing\/afz162","volume":"49","author":"A Patel","year":"2020","unstructured":"Patel A, Berdunov V, Quayyum Z, King D, Knapp M, Wittenberg R. Estimated societal costs of stroke in the UK based on a discrete event simulation. Age Ageing. 2020;49(2):270\u20136.","journal-title":"Age Ageing"},{"issue":"6","key":"1419_CR29","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s00415-009-5053-2","volume":"256","author":"Y Winter","year":"2009","unstructured":"Winter Y, Wolfram C, Schaeg M, Reese JP, Oertel WH, Dodel R, et al. Evaluation of costs and outcome in cardioembolic stroke or TIA. J Neurol. 2009;256(6):954\u201363.","journal-title":"J Neurol"},{"key":"1419_CR30","doi-asserted-by":"crossref","unstructured":"Deshmukh A, Iglesias M, Khanna R, Beaulieu T. Healthcare utilization and costs associated with a diagnosis of incident atrial fibrillation. Heart Rhythm O2. 2022;3(5):577\u201386.","DOI":"10.1016\/j.hroo.2022.07.010"},{"issue":"13","key":"1419_CR31","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1136\/heartjnl-2016-310406","volume":"103","author":"RB Schnabel","year":"2017","unstructured":"Schnabel RB, Pecen L, Ojeda FM, Lucerna M, Rzayeva N, Blankenberg S, et al. Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. Heart. 2017;103(13):1024\u201330.","journal-title":"Heart"},{"issue":"11","key":"1419_CR32","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1002\/pds.4272","volume":"26","author":"T Mueller","year":"2017","unstructured":"Mueller T, Alvarez-Madrazo S, Robertson C, Bennie M. Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland: applying a coherent framework to drug utilisation studies. Pharmacoepidemiol Drug Saf. 2017;26(11):1378\u201386.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"1419_CR33","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1185\/03007995.2015.1082995","volume":"31","author":"CA Spivey","year":"2015","unstructured":"Spivey CA, Liu X, Qiao Y, Mardekian J, Parker RB, Phatak H, et al. Stroke associated with discontinuation of warfarin therapy for atrial fibrillation. Curr Med Res Opin. 2015;31(11):2021\u20139.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"1419_CR34","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1093\/europace\/euw211","volume":"18","author":"AD Blann","year":"2016","unstructured":"Blann AD, Boriani G, Lip GY. Modelling projections for the uptake of edoxaban in an European population to 2050: effects on stroke, thromboembolism, and health economics perspectives. Europace. 2016;18(10):1507\u201313.","journal-title":"Europace"},{"issue":"4","key":"1419_CR35","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3111\/13696998.2012.680555","volume":"15","author":"S Deitelzweig","year":"2012","unstructured":"Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, et al. Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. J Med Econ. 2012;15(4):776\u201385.","journal-title":"J Med Econ"},{"issue":"7","key":"1419_CR36","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.amjmed.2019.01.003","volume":"132","author":"D Pastori","year":"2019","unstructured":"Pastori D, Farcomeni A, Pignatelli P, Violi F, Lip GY. ABC (Atrial fibrillation Better Care) pathway and healthcare costs in atrial fibrillation: the ATHERO-AF study. Am J Med. 2019;132(7):856\u201361.","journal-title":"Am J Med"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-024-01419-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-024-01419-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-024-01419-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T16:18:44Z","timestamp":1729700324000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-024-01419-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,2]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1419"],"URL":"https:\/\/doi.org\/10.1007\/s40273-024-01419-2","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,2]]},"assertion":[{"value":"14 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Pfizer and Bristol Myers Squibb. Employees of the respective funding bodies were involved in the design of the study, writing of the manuscript, and decision-making regarding publication of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"RM, GC, TQ, and CG have received research grants from Bristol Myers Squibb and Pfizer UK. TQ is a data monitoring committee chair for Novo Nordisk. KP was previously employed by Bristol Myers Squibb. SL was previously employed by Bristol Myers Squibb and owns stocks and shares in Pfizer and Bristol Myers Squibb.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The proposal for this study was approved by the University of Glasgow Medicine, Veterinary Medicine and Life Sciences (MVLS) College Ethics Committee, although ethical approval is not required for the analysis of secondary Scottish administrative health data. It was conducted in accordance with International Society for Pharmacoepidemiology (ISPE) Guidelines for Good Pharmacoepidemiology Practices (GPP) and applicable regulatory requirements.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The data utilised in the study is confidential, and analyses were subject to disclosure control by PHS. Data access can be requested by application to PHS via the Public Benefit and Privacy Panel.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"All authors made substantial contributions to study conception and design. Material preparation, data collection and analysis were performed by RM, GC, and CG. The first draft of the manuscript was written by RM, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}